Specific chromosomal abnormalities in patients with acute nonlymphocytic leukemia from the Islamic Republic of Iran. 2006

Movafagh Abolfazl, and Isfahani Fatemeh, and Attarian Hamid, and Ghadiani Mojtaba, and Mosavi Jarahi Alireza, and Mohagheghi Mohammad Ali
Department of Medical Genetics, Taleghni Hospital, and Department of Health and Community Medicine, Shaheed Behesthi Medical University Tehran, Iran. Movafagh_a _@yahoo.com

Cytogenetic analysis performed at diagnosis is considered to be the most valuable prognostic factor in acute non-lymphocytic leukemia (ANLL), a very heterogeneous disease. Little data exist in Iran regarding the cytogenetic characteristics of ANLL . Therefore, cytogenetic investigations were performed for 58 patients with various subtypes of ANLL with unstimulated short term culture and high resolution cell synchronization techniques. Among the 58 evaluated patients, 45 (77.5%) showed clonal karyotypic abnormalities and the percentages of the abnormal cells were recorded within the range of 30%-100%. Some 14 were classified as M1, 20 as M2, 19 as M3 , 3 as M4, 1 as M5 and 1 as M6. The most common chromosome rearrangements were t(15;17), t( 8;21) and t(9;22). Trisomy of chromosome 8 (+8) was the most frequent numerical alteration in 3 patients with M1, M2 and M6. The incidence of other chromosomal defects, including -10, DMCs , -19 , 5q- , dicentric(dic), chromatid breaks, and marker chromosomes was relatively high. Similarities and dissimilarities of our study with others may be due to the role of genetic sensitivities as well as uneven geographic distribution in the pathogenesis of ANLL. Further prospective studies are warranted to precisely elucidate ethnic differences in the pathogenesis of this disease in different populations.

UI MeSH Term Description Entries
D007492 Iran A country bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan. The capital is Tehran. Islamic Republic of Iran
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Movafagh Abolfazl, and Isfahani Fatemeh, and Attarian Hamid, and Ghadiani Mojtaba, and Mosavi Jarahi Alireza, and Mohagheghi Mohammad Ali
January 1991, Hematological oncology,
Movafagh Abolfazl, and Isfahani Fatemeh, and Attarian Hamid, and Ghadiani Mojtaba, and Mosavi Jarahi Alireza, and Mohagheghi Mohammad Ali
June 1986, Cancer genetics and cytogenetics,
Movafagh Abolfazl, and Isfahani Fatemeh, and Attarian Hamid, and Ghadiani Mojtaba, and Mosavi Jarahi Alireza, and Mohagheghi Mohammad Ali
February 1988, Leukemia,
Movafagh Abolfazl, and Isfahani Fatemeh, and Attarian Hamid, and Ghadiani Mojtaba, and Mosavi Jarahi Alireza, and Mohagheghi Mohammad Ali
December 1991, Cancer genetics and cytogenetics,
Movafagh Abolfazl, and Isfahani Fatemeh, and Attarian Hamid, and Ghadiani Mojtaba, and Mosavi Jarahi Alireza, and Mohagheghi Mohammad Ali
August 1988, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
Movafagh Abolfazl, and Isfahani Fatemeh, and Attarian Hamid, and Ghadiani Mojtaba, and Mosavi Jarahi Alireza, and Mohagheghi Mohammad Ali
October 1987, Cancer genetics and cytogenetics,
Movafagh Abolfazl, and Isfahani Fatemeh, and Attarian Hamid, and Ghadiani Mojtaba, and Mosavi Jarahi Alireza, and Mohagheghi Mohammad Ali
June 1987, Cancer genetics and cytogenetics,
Movafagh Abolfazl, and Isfahani Fatemeh, and Attarian Hamid, and Ghadiani Mojtaba, and Mosavi Jarahi Alireza, and Mohagheghi Mohammad Ali
November 1981, The New England journal of medicine,
Movafagh Abolfazl, and Isfahani Fatemeh, and Attarian Hamid, and Ghadiani Mojtaba, and Mosavi Jarahi Alireza, and Mohagheghi Mohammad Ali
December 1982, Cancer genetics and cytogenetics,
Movafagh Abolfazl, and Isfahani Fatemeh, and Attarian Hamid, and Ghadiani Mojtaba, and Mosavi Jarahi Alireza, and Mohagheghi Mohammad Ali
April 1982, Cancer genetics and cytogenetics,
Copied contents to your clipboard!